Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial☆ The CHAARTED trial investigated the long-term survival of patients with metastatic hormone-sensitive prostate cancer (HSPC) treated with androgen deprivation therapy (ADT) with or without docetaxel (Taxotere). This analysis focuses on 10-year overall survival (OS) stratified by disease volume and on-therapy prostate-specific antigen (PSA) levels at 6 months. Annals of Oncology November 7, 2025 Original source
Mechanism-enhanced population science: strengthening population studies through functional insights The success of epidemiological studies in identifying causal relationships between tobacco smoking,1 alcohol consumption, excess body weight, and cancer risk represents one of the greatest achievements in modern public health. However, as the field aims to discover novel risk factors, studies face challenges in detecting modest effect sizes while controlling for unmeasured confounding.2 We propose integrating mechanistic insights from experimental… Annals of Oncology November 7, 2025 Original source
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ Every year, >2.2 million people are diagnosed with lung cancer and >1.8 million people die of the disease,1 making it the leading cause of cancer-related death in men and women worldwide. A reduction in male lung cancer mortality, including in some European Union countries, has been reported along with reduced smoking rates;2 however, lung cancer mortality in European women continues… Annals of Oncology November 7, 2025 Original source
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients The A-BRAVE trial evaluated the efficacy of avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody, as adjuvant treatment of patients with early triple-negative breast cancer (TNBC) at high risk. Annals of Oncology November 7, 2025 Original source
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma Adjuvant immunotherapy is currently the standard of care for patients with resected renal cell carcinoma (RCC) at increased risk of recurrence, but there are no biomarkers available to guide treatment. Kidney injury molecule-1 (KIM-1) has previously been described as a potential circulating biomarker in RCC. Annals of Oncology November 7, 2025 Original source
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma☆ Lenvatinib plus pembrolizumab demonstrated antitumor activity in advanced melanoma after prior anti-programmed cell death protein or ligand 1 [PD-(L)1] therapy in LEAP-004. Here, we report results from LEAP-003 (NCT03820986) which evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in unresectable advanced melanoma. Annals of Oncology November 7, 2025 Original source
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers Protein arginine methyltransferase 5 inhibition often leads to a decrease in cell growth and survival in cancer cell lines. GSK3326595 is a first-generation protein arginine methyltransferase 5 inhibitor. Annals of Oncology November 7, 2025 Original source
Shaping the future of 177Lu-PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key? Lutetium-177 prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy has rapidly established itself as a potent and well-tolerated treatment for metastatic castration-resistant prostate cancer (mCRPC). Early compassionate use,1 a phase II study,2 the TheraP3,4 and the landmark VISION trial5 established the efficacy of 177Lu-PSMA-617 in mCRPC previously treated with docetaxel. This led to global regulatory approval and adoption in the therapeutic armamentarium… Annals of Oncology November 7, 2025 Original source
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008☆ To determine whether adjuvant chemoradiation (CRT) with weekly cisplatin improves recurrence-free survival (RFS) compared with radiation (RT) in pathologically proven intermediate risk early-stage cervical cancer following radical hysterectomy and lymphadenectomy. Annals of Oncology November 7, 2025 Original source
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor (HR)-positive /human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This study aimed to assess whether patients with RS ≥ 31 would have improved outcomes with the addition of anthracyclines to taxane-based… Annals of Oncology November 7, 2025 Original source
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial Intensive follow-up of patients after curative surgery for colorectal cancer is recommended by various scientific societies. However, these recommendations are based mainly on expert opinions, while the results of the few clinical trials are controversial. Moreover, no survival benefit has been demonstrated to date. Annals of Oncology November 7, 2025 Original source
Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer In an era of precision oncology, the follow-up of metastatic colorectal cancer (mCRC) presents a paradox: while treatment is increasingly tailored to molecular subtypes, monitoring for progression still follows a uniform, one-size-fits-all schedule. The entrenched 2- to 3-month restaging interval is a convention rooted more in habit than in evidence. This rigid timetable overlooks the substantial heterogeneity of mCRC, leading… Annals of Oncology November 7, 2025 Original source
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial☆ Nivolumab plus cabozantinib (NIVO+CABO) showed significant benefits over sunitinib (SUN) in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for previously untreated advanced renal cell carcinoma (RCC) in the phase III CheckMate 9ER trial (NCT03141177). We report final, updated efficacy and safety results with median follow-up of 5.6 years. Annals of Oncology November 7, 2025 Original source
ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors The combination of radiotherapy (RT) with targeted agents or immunotherapy may result in improved outcomes, but it can also increase toxicity. However, there is a paucity of high-quality toxicity data, leading to an absence of evidence-based guidelines. Annals of Oncology November 7, 2025 Original source
An unforeseen, existential threat to oncological research in Europe In this letter, we aim to draw readers’ attention to the existential threat that oncological research in Europe faces due to the unintended consequences arising from the implementation of Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR), and to highlight the ongoing efforts by the European Society for Medical Oncology (ESMO) to mitigate these challenges. Annals of Oncology November 7, 2025 Original source
Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning We thank the authors for their useful comments and reflections on our publication,1 and appreciate the opportunity to expand on parts of the topic in addition to the original research. Annals of Oncology November 7, 2025 Original source
A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer We read the article by Germani and colleagues with great interest.1 The analysis of non-linear progression risk is particularly insightful. However, we wish to discuss a potential logical inconsistency within the proposed clinical algorithm that may have important implications for its translation into practice. Annals of Oncology November 7, 2025 Original source
SUNNIFORECAST trial design supported by real-world data in papillary renal cell carcinoma We read with interest the recent report from the SUNNIFORESCAST trial (Bergmann et al. Ann Oncol. 2025), which compared ipilimumab–nivolumab with standard-of-care therapies in untreated non-clear cell renal cell carcinoma (nccRCC).1 We commend the authors for conducting a much-needed randomized trial in this understudied population and agree with their choice of control arm, given the absence of a universally accepted… Annals of Oncology November 7, 2025 Original source
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer Breast cancer is a global disease affecting millions of individuals. Ongoing advancements in multidisciplinary management of breast cancer patients warrant discussion and integration into standard treatment plans. Annals of Oncology November 7, 2025 Original source
Corrigendum to “Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population” The authors regret that in the Results section of the Abstract in the original publication, the number of KRAS-wt patients was incorrectly given. The correct Abstract should read as follows: Annals of Oncology November 7, 2025 Original source